TY - JOUR T1 - Drug advances in inflammatory bowel disease JF - Clinical Medicine JO - Clin Med SP - 378 LP - 382 DO - 10.7861/clinmedicine.13-4-378 VL - 13 IS - 4 AU - R Alexander Speight AU - John C Mansfield Y1 - 2013/08/01 UR - http://www.rcpjournals.org/content/13/4/378.abstract N2 - The pathogenesis of inflammatory bowel disease (IBD) remains incompletely understood, but is thought to be a consequence of immune dysregulation, impaired mucosal integrity, enteric bacterial dysbiosis and genetic susceptibility factors. Recent drug advances in the treatment of IBD have clarified the role of existing medication, including 5-amino-salicylic acids (5-ASAs) and has seen a burgeoning use of treatment with biologicals. With recent advances in our understanding of these debilitating diseases, it is hoped that novel therapeutic targets can be identified. ER -